International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 2 , Pages 343-354 , 1 February 2006

Radiation sensitization with redox modulators: A promising approach

  • Abby Rosenberg, B.A.
    • ,
  • Susan Knox, Ph.D., M.D.

      Affiliations

    • Corresponding Author InformationReprint requests to: Susan J. Knox, M.D., Ph.D., Stanford University Medical Center, Department of Radiation Oncology, CCSR, South 1245, 269 Campus Drive West, Stanford, CA 94305-5152. Tel: (650) 723-5832; Fax: (650) 723-7362

Received 14 June 2004 ,Revised 14 October 2005 ,Accepted 21 October 2005.

References 

  1. Thomlinson RH , Gray LH . The histological structure of some human lung cancers and possible implications for radiotherapy . Br J Cancer . 1955;9:539–549
  2. Brown JM . Exploiting the hypoxic cancer cell (Mechanisms and therapeutic strategies) . Mol Med Today . 2000;6:157–162
  3. Connell PP , Martel MK , Hellman S . Cancer (Principles and practice of oncology) . In:  De Vita VT ,  Hellman S ,  Rosenberg S editor. Principles of cancer management (Radiation therapy) . Philadelphia: Lippincott, Williams and Wilkins; 2001;p. 274–275
  4. Brown JM . Selective radiosensitization of the hypoxic cells of mouse tumors with the nitroimidazoles metronidazole and Ro7-0582 . Radiat Res . 1975;64:633–647
  5. Dische S , Saunders MI , Lee ME , et al.   Clinical testing of the radiosensitizer Ro 07-0582 (Experience with multiple doses) . Br J Cancer . 1977;35:567–579
  6. Brown JM . Clinical trials of radiosensitizers (What should we expect?) . Int J Radiat Oncol Biol Phys . 1984;10:425–429
  7. Brown JM . The hypoxic cell (A target for selective cancer therapy—Eighteenth Bruce F. Cain memorial award lecture) . Cancer Res . 1999;59:5863–5870
  8. Delahoussaye YM , Wouters BG , Evans JE , et al.   Intranuclear metabolism of tirapazamine by matrix-associated reductases . [Abstract] Proc Am Assoc Cancer Res . 1997;38:163
  9. Brown JM , Lemmon MJ . Potentiation by the hypoxic cytotoxin SR 4233 of cell killing produced by fractionated irradiation of mouse tumors . Cancer Res . 1990;50:7745–7749
  10. O’Rourke JF , Dachs GU , Gleadle JM , et al.   Hypoxia response elements . Oncol Res . 1997;9:327–332
  11. Holden SA , Teicher BA , Ara G . Enhancement of alkylating agent activity by SR-4233 in the FSaIIC murine fibrosarcoma . J Natl Cancer Inst . 1992;84:187–193
  12. Dorie MJ , Brown JM . Tumor-specific, schedule-dependent interaction between tirapazamine (SR-4233) and cisplatin . Cancer Res . 1993;53:4633–4636
  13. Goldberg Z , Evans J , Birrell G , et al.   An investigation of the molecular basis for the synergistic interaction of tirapazamine and cisplatin . Int J Radiat Oncol Biol Phys . 2001;49:175–182
  14. Gandara DR , Lara PN , Goldberg Z , et al.   Tirapazamine (Prototype for a novel class of therapeutic agents targeting tumor hypoxia) . Semin Oncol . 2002;29:102–109
  15. Rodriguez GI , Valdivieso M , Von Hoff DD , et al.   A phase I/II trial of the combination of tirapazamine and cisplatin in patients with non-small cell lung cancer . [Abstract] Prox Am Soc Clin Oncol . 1996;15:382a
  16. Treat J , Johnson E , Langer C , et al.   Tirapazamine with cisplatin in patients with advanced non-small cell lung cancer (A phase II study) . J Clin Oncol . 1998;16:3524–3527
  17. Von Pawel J , Von Roemeling R , Gatzemeier U , et al.   Tirapazamine plus cisplatin versus cisplatin in advanced non-small cell lung cancer (A report of the international CATAPULT I study group) . J Clin Oncol . 2000;18:1351–1359
  18. Sheperd F , Koschel G , Von Pawel J , et al.   Comparison of tirazone (tirapazamine) and cisplatin versus etoposide and cisplatin in advanced non-small cell lung cancer: Final results of the international phase III CATAPULT trial. Proceedings of the International Association for the Study of Lung Cancer, 9th World Conference on Lung Cancer, Tokyo, Japan, September 2000 . [Abstract] Lung Cancer . 2000;28(Suppl 1):28
  19. Williamson SK , Crowley JJ , Lara PN , et al.   S0003: Paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A phase III southwest oncology group (SWOG) trial . [Abstract] Proc Am Soc Clin Oncol . 2003;22:622
  20. Shulman LN , Buswell L , Riese N , et al.   Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors . Int J Radiat Oncol Biol Phys . 1999;44:349–353
  21. Pinto HA , Le Q , Terris D , et al.   Randomized trial of tirapazamine/cisplatin/fluorouracil versus cisplatin/fluorouracil for organ preservation in advanced respectable head and neck cancer . [Abstract] Pro Am Soc Clin Oncol . 2002;21:227a
  22. Rischen D , Peters L , Hicks R , et al.   Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer . J Clin Oncol . 2001;19:535–542
  23. Rischin D , Peters L , Fisher R , et al.   Tirapazamine, cisplatin and radiation versus fluorouracil, cisplatin and radiation in patients with locally advanced head and neck cancer (A randomized phase II trial of the trans-tasman radiation oncology group (TROG 98.02)) . J Clin Oncol . 2005;23:79–87
  24. Craighead PS , Pearcey R , Stuart G . A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervical cancer . Int J Radiat Oncol Biol Phys . 2000;48:791–795
  25. Inde DC , Pass HI , Glatstein E . Cancer of the lung . In:  DeVita VT ,  Hellman S ,  Rosenberg SA editor. Cancer (Principles and practices of oncology) . Philadelphia: Lippincott-Raven; 1997;p. 849–949
  26. Le QT , McCoy J , Williamson S , et al.   Phase I study of tirapazamine plus cisplatin/etoposide and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004) (A Southwest Oncology Group study) . Clin Cancer Res . 2004;10:5418–5424
  27. Patterson LH , Raleigh SM . Reductive metabolism (Its application to prodrug activation) . In:  Gooderham NJ editors. Drug metabolism (Towards the next millennium) . Amsterdam: IOS Press; 1998;p. 72–79
  28. Patterson LH . Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents (A new class of bioreductive agent) . Cancer Metastasis Rev . 1993;12:119–134
  29. Patterson LH , McKeown SR . AQ4N (A new approach to hypoxia-activated cancer chemotherapy) . Br J Cancer . 2000;83:1589–1593
  30. Smith PJ , Desnoyers R , Blunt N , et al.   DNA topoisomerase II-dependent cytotoxicity to alkylaminoanthraquinones and their N-oxides . Cancer Chemother Pharmacol . 1997;39:455–461
  31. Patterson LH . Bioreductively activated antitumor N-oxides (The case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy) . Drug Metab Rev . 2002;34:581–592
  32. McKeown SR , Friery OP , McIntyre IA , et al.   Evidence for a therapeutic gain when AQ4N or tirapazamine is combined with radiation . Br J Cancer . 1996;(Suppl 27):S39–S42
  33. Hejmadi MV , McKeown SR , Friery OP , et al.   DNA damage following combination of radiation with the bioreductive drug AQ4N (Possible selective toxicity to oxic and hypoxic cells) . Br J Cancer . 1996;73:499–505
  34. McKeown SR , Hejmadi MV , McIntyre IA , et al.   AQ4N (An alkylaminoanthraquinon N-oxide showing bioreductive potential and positive interaction with radiation in vivo) . Br J Cancer . 1995;72:76–81
  35. KuDOS Pharmaceutical, Inc. Available at: http://www.kudospharma.co.uk/r_d/banox.php. Web page title: Banoxantrone. Accessed December 1, 2005.
  36. Shaw E , Scott C , Suh J , et al.   RSR13 plus cranial radiation therapy in patients with brain metastases (Comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database) . J Clin Oncol . 2003;21:2364–2371
  37. Whar J , Gerber M , Venitz J , et al.   Allosteric modification of oxygen delivery by hemoglobin . Anesth Analg . 2001;92:615–620
  38. Abraham DJ , Wireko FC , Randad RS , et al.   Allosteric modifiers of hemoglobin (2-[4-[[(3,5-disubstituted aniline) carbonyl]-methyl]phenoxyl]-2-methylproprionic acid derivatives that lower the oxygen affinity decreasing agents) . J Med Chem . 1991;34:752–757
  39. Rockwell S , Kelley M . RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy (Preliminary studies with EMT6 cells and tumors and normal tissues in mice) . Radiat Oncol Invest . 1998;6:199–208
  40. Teicher BA , Gulshan A , Emi Y , et al.   RSR13 (Effects on tumor oxygenation and response to therapy) . Drug Dev Res . 1996;38:1–11
  41. Khandelwal SR , Lin P-S , Hall CE , et al.   Increased radiation response of FSaII fibrosarcoma in C3H mice following administration of an allosteric effector of hemoglobin-oxygen affinity . Radiat Oncol Invest . 1996;4:51059
  42. Suh J , Stea B , Nabid J . Standard whole brain radiation therapy (WBRT) with supplemental oxygen with or without RSR13 (Efaproxiral) in patients with brain metastases (Results of the randomized REACH (RT-009) Study) . [Abstract] J Clin Oncol . 2004;22:1534
  43. Shaw E , Scott C , Stea B , et al.   Survival improvement with RSR13 plus radiation therapy in patients with brain metastases (Comparison to the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database) . 2000; [Abstract 615]. 2000 ASCO Annual Meeting, May 20–23, New Orleans, LA
  44. Kleinberg L , Grossman SA , Piantadosi S , et al.   Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme . J Clin Oncol . 1999;17:2593–2603
  45. Kleinberg L , Grossman SA , Carson K , et al.   Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy (Results of a phase II new approaches to brain tumor therapy CNS Consortium Safety and Efficacy Study) . J Clin Oncol . 2002;20:3149–3155
  46. Sagar SM , Israel MA . Primary and metastatic tumors of the nervous system . In:  Kasper DL ,  Fauci AS ,  Longo DL ,  Braunwald E ,  Hauser SL ,  Jameson JL editor. Harrison’s principles of internal medicine . New York: McGraw Hill Companies, Inc; 2005;p. 2453
  47. New PZ , Grossman S , Mikkelsen T , et al.   Evaluation of safety and tolerance of escalating doses of RSR13 administered with a fixed dose of BCNU every 6 weeks in patients with recurrent malignant glioma (Results of the phase I NABTT 9806 clinical trial) . [Abstract] J Clin Oncol . 2004;22:1533
  48. Stea B , Nabid A , Kresl J , et al.   Safety profile of efaproxiral (RSR13), a novel radiation sensitizer, in patients undergoing radiation therapy . [Abstract] J Clin Oncol . 2004;22:3090
  49. Venitz J , Slattum PW , Gerber M , et al.   Pharmacokinetics of escalating IV doses of an allosteric hemoglobin modifier (RSR13) in healthy volunteers . [Abstract] Pharm Res . 1996;13:s479
  50. Magda D , Lepp C , Nokolay G , et al.   Redox cycling by motexafin gadolinium enhances cellular response to ionizing radiation by forming reactive oxygen species . Int J Radiation Oncology Biol Phys . 2001;51:1025–1036
  51. Miller R , Woodburn K , Fan Q , et al.   Motexafin gadolinium (A redox active drug that enhances the efficacy of bleomycin and doxorubicin) . Clinical Cancer Research . 2001;7:3215–3221
  52. Miller R , Woodburn K , Fan Q , et al.   In vivo animal studies with gadolinium (III) texaphyrin as a radiation enhancer . Int J Radiat Oncol Biol Phys . 1999;45:981–989
  53. Viala J , Vanel D , Meingan P , et al.   Phases IB and II multidose trial of gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging (Preliminary results in brain metastases) . Radiology . 1999;212:755–759
  54. Motexafin gadolinium . Drugs R & D . 2004;5:52–57
  55. Xu S , Zakian K , Thaler H , et al.   Effects of motexafin gadolinium on tumor metabolism and radiation sensitivity . Int J Radiat Oncol Biol Phys . 2001;49:1381–1390
  56. Perez O , Nolan G , Magda D . Motexafin gadolinium (Gd-Tex) selectively induces apoptosis in HIV-1 infected CD4+ T helper cells . Proc Natl Acad Sci . 2002;99:2270–2274
  57. Koutcher JA , Alfieri AA , Devitt ML , et al.   Changes in radiation sensitization induced by Fluosol-DA as measured by 31-P NMR . Cancer Res . 1990;50:7252–7256
  58. Donnelly ET , Liu Y , Fatunmbi YO , et al.   Effects of texaphyrins on the oxygenation of EMT6 mouse mammary tumors . Int J Radiat Oncol Biol Phys . 2004;58:1570–1576
  59. Woodburn K , Luo Y , Fan Q , et al.   In vitro and in vivo enhancement of apoptotic response to radiation and motexafin gadolinium . 2001; [Abstract]. 2001 ASCO annual meeting, May 12–15, San Francisco, CA
  60. Young SW , Qing F , Harriman A , et al.   Gadolinium (III) texaphyrin (A tumor selective radiation sensitizer that is detectable by MRI) . Proc Natl Acad Sci U S A . 1996;93:6610–6615
  61. Bernhard EJ , Mitchel JB , Deen D , et al.   Re-evaluating gadolinium (III) texaphyrin as a radiosensitizing agent . Cancer Res . 2000;60:86–91
  62. Rockwell S , Donnelly E , Yanfeng L , et al.   Preliminary studies of the effects of gadolinium texaphyrin on the growth and radiosensitivity of EMT6 cells in vitro . Int J Radiat Oncol Biol Phys . 2002;54:536–541
  63. Mehta M , Rodrigus P , Terhaard CHJ , et al.   Survival and neurologic outcomes in a randomized trial of motexafin gadolinium and whole brain radiation therapy in brain metastases . J Clin Oncol . 2003;21:2529–2536
  64. Meyers C , Smith J , Bezjak A , et al.   Neurocognitive function and progression in patients with brain metastases treated with whole brain radiation and motexafin gadolinium (Results of a randomized phase III trial) . J Clin Oncol . 2004;22: 157–156
  65. Rosenthal D , Becerra C , Toto R , et al.   Reversible renal toxicity resulting from high single doses of the new radiosensitizer, gadolinium texaphyrin . Am J Clin Oncol (CCT) . 2000;23:593–598
  66. Carde P , Timmerman R , Mehta M , et al.   Multicenter phase Ib/II trial of the radiation sensitizer motexafin gadolinium in patients with brain metastases . J Clin Oncol . 2001;19:2074–2083
  67. Pharmacylics. Pharmacyclics announces interim data from phase 1 clinical trial of Xcytrin plus Rituxan and Zevalin for the treatment of B-cell lymphoma. Available at: http://www.pharmacyclics.com/webpage_templates/tert.php3?page_name=pr_1095651527. Accessed November 14, 2005.
  68. Fakih M , Ramanathan RK , Mani S , et al.   Phase I pharmacokinetic trial of thrice weekly motexafin gadolinium with daily radiation therapy in advanced biliary tree and pancreatic cancers . 2001; [Abstract]. 2001 ASCO annual meeting, May 12–15, San Francisco, CA
  69. Ford JM , Seiferheld W , Mehta M , et al.   Comparison of survival of patients in the phase I study of motexafin gadolinium with radiation therapy for glioblastoma multiforme, with a matched cohort of patients from the RTOG RPA database . [Abstract] Proc Am Soc Clin Oncol . 2003;22:106
  70. Suh J , Chang E , Timmerman R , et al.   Phase II trial of motefaxin gadolinium (MGd, Xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM) . 2002; [Abstract]. 2002 ASCO annual meeting, May 18–21, Orlando, FL
  71. Phan S , Messina M , Buffan M , et al.   A phase I trial combining motexafin gadolinium with docetaxel in the treatment of advanced solid tumors . 2004; [Abstract]. 2004 ASCO annual meeting, June 5–8, New Orleans, LA
  72. Giaccia A , Siim BG , Johnson RS . HIF-1 as a target for drug development . Nat Rev Drug Discovery . 2003;2:1–9
  73. Yeo E-J , Chun Y-S , Park J-W . New anti-cancer strategies targeting HIF-1 . Biochem Pharmacol . 2004;68:1061–1069
  74. Huang LE , Gu J , Schau M , et al.   Regulation of hypoxia-inducible factor 1 alpha is mediated by an O2 dependent degradation domain via the ubiquitin-proteasome pathway . Proc Natl Acad Sci U S A . 1998;95:7987–7992
  75. Salceda S , Caro J . Hypoxia-inducible factor 1 alpha protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes . J Biol Chem . 1997;272:22642–22647
  76. Laughner E , Taghavi P , Chiles K , et al.   HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1 alpha synthesis (Novel mechanism for HIF-1 mediated vascular endothelial growth factor expression) . Mol Cell Biol . 2001;21:3995–4004
  77. Chan DA , Sutphin PD , Denko ND , et al.   Role of prolyl hydroxylation in oncogenically stabilized hypoxia-inducible factor-1 alpha . J Biol Chem . 2002;277:40112–40117
  78. Sun X , Kanwar JR , Leung E , et al.   Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy . Gene Ther . 2001;8:638–645
  79. Chun YS , Choi E , Kim TY , et al.   A dominant-negative isoform lacking exons 11 and 12 of the human hypoxia-inducible factor-1 alpha gene . Biochem J . 2002;362:71–79
  80. Minet E , Mottet D , Michel G , et al.   Hypoxia-induced activation of HIF-1 (Role of HIF-1 alpha-HSP90 interaction) . FEBS Lett . 1999;460:251–256
  81. Isaacs JS , Jung YJ , Mimnaugh EG , et al.   HSP90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha degradative pathway . J Biol Chem . 2002;277:29936–29944
  82. Zhong H , Chiles K , Feldser D , et al.   Modulation of hypoxia-inducible factor 1 alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells (Implications for tumor angiogenesis and therapeutics) . Cancer Res . 2000;60:1541–1545
  83. Treins C , Giorgetti-Peraldi S , Murdaca J , et al.   Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway . Biol Chem . 2002;277:27975–27981
  84. Chun YS , Yeo EJ , Choi E , et al.   Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells . Biochem Pharmacol . 2001;61:947–954
  85. Eo EJ , Chun YS , Cho YS , et al.   YC-1 (A potential anticancer drug targeting hypoxia-inducible factor 1) . J Natl Cancer Inst . 2003;95:516–525
  86. Mabjeesh NJ , Post DE , Willard MT , et al.   Geldanamycin induces degradation of hypoxia-inducible factor 1 alpha protein via the proteosome pathway in prostate cancer cells . Cancer Res . 2002;62:2478–2482
  87. Fukuda R , Hirota K , Fan F , et al.   Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells . J Biol Chem . 2002;512:157–162
  88. Stiehl DP , Jelkmann W , Wenger RH , et al.   Normoxic induction of the hypoxia inducible factor 1 alpha by insulin and interleukin 1 beta involves the phsphatidylinositol 3-kinase pathway . FEBS Lett . 2002;512:157–162
  89. Rapisarda A , Uranchimeg B , Scudiero DA , et al.   Identification of small molecule inhibitors of hypoxia-inducible factor 1 transcriptional activation pathway . Cancer Res . 2002;62:4316–4324
  90. Bachtiary B , Schindl M , Potter R , et al.   Overexpression of hypoxia-inducible factor 1 alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radiotherapy for cervical cancer . Clin Can Res . 2003;9:2234–2240
  91. Williams KJ , Telfer BA , Xenaki D , et al.   Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor 1 . Radiother Oncol . 2005;75:89–98
  92. Moeller BJ , Cao Y , Li CY , et al.   Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors (Role of reoxygenation, free radicals, and stress granules) . Cancer Cell . 2004;5:429–441
  93. Moeller BJ , Dreher MR , Rabbani ZN , et al.   Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity . Cancer Cell . 2005;8:99–110
  94. Li X , Luwor R , Lu Y , et al.   Enhancement of antitumor activity of the anti-EGF receptor monoclonal antibody cetuximab/C335 by perifosine in PTEN-deficient cancer cells . Oncogene . 2005; Sep 19; [Epub ahead of print]
  95. Rooseboom M , Commandeur JN , Vermeulen NP . Enzyme-catalyzed activation of anticancer prodrugs . Pharmacol Rev . 2004;56:53–102

PII: S0360-3016(05)02817-8

doi: 10.1016/j.ijrobp.2005.10.013

International Journal of Radiation Oncology * Biology * Physics
Volume 64, Issue 2 , Pages 343-354 , 1 February 2006

Article Tools